AzTrials
AzTrials

Sedentary BehaviorSECODISNCT05931406

Effects of a Sedentary Behaviors at Work on Health in Emergency Medical Dispatchers and CODIS Operators (SECODIS)

A study testing Sit-and-stand desk and Cycloergometer in people with Sedentary Behavior and Occupational Stress, run by University Hospital, Clermont-Ferrand at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of the study is to study changes in sedentary behavior following a behavioral intervention (sit-and-stand desk, and cycloergometer) Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Sedentary Behavior, Occupational Stress
What is being tested?
Sit-and-stand desk and Cycloergometer
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
1 siteFrance
Study dates
7 Mar 2024to Jun 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Emergency medical dispatchers, Operators of Non-Scheduled Care (OSNP), Ambulance Coordinators (COAM) or firefighters from the departmental fire and rescue operational center (CODIS).
  • Person able to give an informed consent to participate in research
  • Affiliated with a Social Security scheme.
  • Being able to use the sit-stand desk and the cycle ergometer

Who cannot join

  • Non-affiliated to a health insurance,
  • Protected persons (minors, pregnant women, breastfeeding women, guardianship, curatorship, deprived of freedoms, safeguard of justice),
  • Refusal to participate.
  • History of PTSD.
  • History of psychiatric disorders.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • CHU clermont-ferrand

    Clermont-Ferrand

    Lise Laclautre

    Frédéric Dutheil

    Recruiting

Other trials in France

About this study

Official title: Effects of a Sedentary Behaviors at Work on Health in Emergency Medical Dispatchers and CODIS Operators

The purpose of the study is to study changes in sedentary behavior following a behavioral intervention (sit-and-stand desk, and cycloergometer)

Read the detailed description

Each emergency medical services dispatcher and each firefighter participates in the study for three days. A normal working day from of 12h is compared to: (i) a working day during which the participants have to get up at least 5 min/hour (sit-and-stand desk), (ii) a working day during which they can use a cycloergometer installed under the desk. Conditions will be random using Latin Square design with stratification between sequences cross-over design on occupation (EMD vs. firefighters).

The heart rate variability (measured using Zephyr®), the electrodermal activity (Empatica® E4), the level of physical activity (Actigraph®) as well as the blood sugar (Freestyle®) will be measured continuously during the 12 hours of work and the night after except for Actigraph® and Freestyle® device that will be let one week. Blood and saliva samples will be collected on each working day, at the beginning and end of the day i.e. two measures for blood samples, and every three hours i.e. 5 measures for saliva sampling. Participants will have to complete a detailed questionnaire to identify the particular events (vital emergencies, etc.) that may influence the parameters measured.

Participants will be asked to answer a general questionnaire once at the start of the study that will cover different aspects:

  • Sociodemographic,
  • Visual analogue scale (VAS) related to psychosocial factors : stress at home, burnout / burnout, decision latitude / autonomy at work, psychological demands at work (workload), support from the hierarchy, support from co-workers, family support, job satisfaction with regard to effort, commitment to work, addiction to work, quality of life, need for psychological support,
  • Eating habits.

They will then have to answer a short questionnaire at the beginning and at the end of each measurement day. It will cover different aspects:

  • Four VAS (stress level, fatigue, anxiety, mood),
  • Physical activity and sedentary lifestyle (number of hours of physical activity and sitting during the last 24 hours),
  • Daily consumption (tobacco, alcohol, cannabis, coffee, tea).
Being tested
Control, Sit-and-stand desk, Cycloergometer
Medical subject headings
Sedentary Behavior, Occupational Stress

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ControlBehavioural

    A normal working day from of 12h

  • Sit-and-stand deskBehavioural

    a working day during which the participants have to get up at least 5 min/hour

  • CycloergometerBehavioural

    a working day during which they can use a cycloergometer installed under the desk

Study groups in NCT05931406
Study groupRoleWhat they receive
Emergency medical dispatchersExperimentalNot described
Receives: Behavioral: Control; Behavioral: Sit-and-stand desk; Behavioral: Cycloergometer
FirefighterExperimentalNot described
Receives: Behavioral: Control; Behavioral: Sit-and-stand desk; Behavioral: Cycloergometer

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sedentary behavior

    Sedentary behavior measured by actimetry using Actigraph® in number of minutes per day standing/active.

    Measured: 12 hours of work corresponding to the control condition

  2. Sedentary behavior

    Sedentary behavior measured by actimetry using Actigraph® in number of minutes per day standing/active.

    Measured: 12 hours of work corresponding to the sit-and-stand desk condition

  3. Sedentary behavior

    Sedentary behavior measured by actimetry using Actigraph® in number of minutes per day standing/active.

    Measured: 12 hours of work corresponding to the cycloergometer condition

Secondary outcomes (169)
  1. Sedentary behavior

    Sedentary behavior measured by actimetry using Actigraph® in number of minutes standing/active during one week.

    Measured: one-week (168 hours) sit-and-stand desk cycle

  2. Sedentary behavior

    Sedentary behavior measured by actimetry using Actigraph® in number of minutes per day standing/active.

    Measured: one-week (168 hours) control cycle

  3. Sedentary behavior

    Sedentary behavior measured by actimetry using Actigraph® in number of minutes standing/active during one week.

    Measured: one-week (168 hours) cycloergometer cycle

  4. Heart rate variability

    The heart rate variability measured using Zephyr®

    Measured: 24 hours record corresponding to 12 hours of work and the next 12 hours of rest

  5. Electrodermal activity

    The electrodermal activity measured using Empatica E4

    Measured: 24 hours record corresponding to 12 hours of work and the next 12 hours of rest

  6. Stress at home

    Stress at home measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the control day

  7. Stress at home

    Stress at home measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the sit-and-stand desk day

  8. Stress at home

    Stress at home measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the cycloergometer day

  9. Stress at home

    Stress at home measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 pm, end of the control day

  10. Stress at home

    Stress at home measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 pm, end of the sit-and-stand desk day

  11. Stress at home

    Stress at home measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 pm, end of the cycloergometer day

  12. Fatigue

    Fatigue measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the control day

  13. Fatigue

    Fatigue measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the sit-and-stand desk day

  14. Fatigue

    Fatigue measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the cycloergometer day

  15. Fatigue

    Fatigue measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 pm, end of the control day

  16. Fatigue

    Fatigue measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 pm, end of the sit-and-stand desk day

  17. Fatigue

    Fatigue measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 pm, end of the cycloergometer day

  18. Anxiety

    Anxiety measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the control day

  19. Anxiety

    Anxiety measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the sit-and-stand desk day

  20. Anxiety

    Anxiety measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the cycloergometer day

  21. Anxiety

    Anxiety measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 pm, end of the control day

  22. Anxiety

    Anxiety measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 pm, end of the sit-and-stand desk day

  23. Anxiety

    Anxiety measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: 6 pm, end of the cycloergometer day

  24. Mood

    Mood measured using visual analogue scale ranging from 0 (Bad) to 100 (Excellent). Higher scores mean a better outcome.

    Measured: 6 pm, beginning of the control day

  25. Mood

    Mood measured using visual analogue scale ranging from 0 (Bad) to 100 (Excellent).Higher scores mean a better outcome.

    Measured: 6 am, beginning of the sit-and-stand desk day

  26. Mood

    Mood measured using visual analogue scale ranging from 0 (Bad) to 100 (Excellent).Higher scores mean a better outcome.

    Measured: 6 am, beginning of the cycloergometer day

  27. Mood

    Mood measured using visual analogue scale ranging from 0 (Bad) to 100 (Excellent).Higher scores mean a better outcome.

    Measured: 6 pm, end of the control day

  28. Mood

    Mood measured using visual analogue scale ranging from 0 (Bad) to 100 (Excellent).Higher scores mean a better outcome.

    Measured: 6 pm, end of the sit-and-stand desk day

  29. Mood

    Mood measured using visual analogue scale ranging from 0 (Bad) to 100 (Excellent).Higher scores mean a better outcome.

    Measured: 6 pm, end of the cycloergometer day

  30. Stress at work

    Stress at work measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum).Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the control day

  31. Stress at work

    Stress at work measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum).Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the sit-and-stand desk day

  32. Stress at work

    Stress at work measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum).Higher scores mean a worse outcome.

    Measured: 6 am, beginning of the cycloergometer desk day

  33. Stress at work

    Stress at work measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum).Higher scores mean a worse outcome.

    Measured: 6 pm, end of the control day

  34. Stress at work

    Stress at work measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum).Higher scores mean a worse outcome.

    Measured: 6 pm, end of the sit-and-stand desk day

  35. Stress at work

    Stress at work measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum).Higher scores mean a worse outcome.

    Measured: 6 pm, end of the cycloergometer day

  36. Amount of physical activity

    Number of hours of physical activity during the last 24 hours

    Measured: 6 am, beginning of the control day

  37. Intensity of physical activity

    Physical activity intensity during the last 24 hours measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a higher intensity.

    Measured: 6 am, beginning of the control day

  38. Amount of physical activity

    Number of hours of physical activity during the last 24 hours

    Measured: 6 am, beginning of the sit-and-stand desk day

  39. Intensity of physical activity

    Physical activity intensity during the last 24 hours measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a higher intensity.

    Measured: 6 am, beginning of the sit-and-stand desk day

  40. Amount of physical activity

    Number of hours of physical activity during the last 24 hours

    Measured: 6 am, beginning of the cycloergometer day

  41. Intensity of physical activity

    Physical activity intensity during the last 24 hours measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a higher intensity.

    Measured: 6 am, beginning of the cycloergometer day

  42. Amount of physical activity

    Number of hours of physical activity during the working day

    Measured: 6 pm, end of the control day

  43. Intensity of physical activity

    Physical activity intensity during the working day measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a higher intensity.

    Measured: 6 pm, end of the control day

  44. Amount of physical activity

    Number of hours of physical activity during the working day

    Measured: 6 pm, end of the sit-and-stand desk day

  45. Intensity of physical activity

    Physical activity intensity during the working day measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a higher intensity.

    Measured: 6 pm, end of the sit-and-stand desk day

  46. Amount of physical activity

    Number of hours of physical activity during the working day

    Measured: 6 pm, end of the cycloergometer day

  47. Intensity of physical activity

    Physical activity intensity during the working day measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a higher intensity.

    Measured: 6 pm, end of the cycloergometer day

  48. Sitting time

    Number of hours sit during the last 24 hours

    Measured: 6 am, beginning of the control day

  49. Sitting time

    Number of hours sit during the last 24 hours

    Measured: 6 am, beginning of the sit-and-stand desk day

  50. Sitting time

    Number of hours sit during the last 24 hours

    Measured: 6 am, beginning of the cycloergometer day

  51. Sitting time

    Number of hours sit during the working day

    Measured: 6 pm, end of the control day

  52. Sitting time

    Number of hours sit during the working day

    Measured: 6 pm, end of the sit-and-stand desk day

  53. Sitting time

    Number of hours sit during the working day

    Measured: 6 pm, end of the cycloergometer day

  54. Tabacco consumption

    Number of cigarette during the last 24h

    Measured: 6 am, beginning of the control day

  55. Tabacco consumption

    Number of cigarette during the last 24h

    Measured: 6 am, beginning of the sit-and-stand desk day

  56. Tabacco consumption

    Number of cigarette during the last 24h

    Measured: 6 am, beginning of the cycloergometer day

  57. Tabacco consumption

    Number of cigarette during the working day

    Measured: 6 pm, end of the control day

  58. Tabacco consumption

    Number of cigarette during the working day

    Measured: 6 pm, end of the sit-and-stand desk day

  59. Tabacco consumption

    Number of cigarette during the working day

    Measured: 6 pm, end of the cycloergometer day

  60. Tea consumption

    Number of cups of tea during the last 24h

    Measured: 6 am, beginning of the control day

  61. Tea consumption

    Number of cups of tea during the last 24h

    Measured: 6 am, beginning of the sit-and-stand desk day

  62. Tea consumption

    Number of cups of tea during the last 24h

    Measured: 6 am, beginning of the cycloergometer day

  63. Tea consumption

    Number of cups of tea during the last 24h

    Measured: 6 pm, end of the control day

  64. Tea consumption

    Number of cups of tea during the last 24h

    Measured: 6 pm, end of the sit-and-stand desk day

  65. Tea consumption

    Number of cups of tea during the last 24h

    Measured: 6 pm, end of the cycloergometer day

  66. Coffee consumption

    Number of cups of coffee during the last 24h

    Measured: 6 am, beginning of the control day

  67. Coffee consumption

    Number of cups of coffee during the last 24h

    Measured: 6 am, beginning of the sit-and-stand desk day

  68. Coffee consumption

    Number of cups of coffee during the last 24h

    Measured: 6 am, beginning of the cycloergometer day

  69. Coffee consumption

    Number of cups of coffee during the working day

    Measured: 6 pm, end of the control day

  70. Coffee consumption

    Number of cups of coffee during the working day

    Measured: 6 pm, end of the sit-and-stand desk day

  71. Coffee consumption

    Number of cups of coffee during the working day

    Measured: 6 pm, end of the cycloergometer day

  72. Sociodemographic

    Sociodemographic will be assessed: gender, age, marital status, children, occupation, and recent stressful event

    Measured: Once at baseline

  73. Sleep quality

    Sleep quality measured using visual analogue scale ranging from 0 (Bad) to 100 (Excellent). Higher scores mean a better outcome.

    Measured: Once at baseline

  74. Family support

    Family support measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a better outcome.

    Measured: Once at baseline

  75. Burnout

    Burnout measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: Once at baseline

  76. Job demand

    Job demand measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a worse outcome.

    Measured: Once at baseline

  77. Job control

    Job control measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a better outcome.

    Measured: Once at baseline

  78. Hierarchy support

    Hierarchy support measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a better outcome.

    Measured: Once at baseline

  79. Colleagues support

    Colleagues support measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a better outcome.

    Measured: Once at baseline

  80. Effort reward-imbalance

    Effort reward-imbalance measured using visual analogue scale ranging from 0 (Minimum) to 100 (Maximum). Higher scores mean a better outcome.

    Measured: Once at baseline

  81. Medical treatment

    Medical treatment measured using multi-choice question "do you take long term medication?"

    Measured: Once at baseline

  82. Allergy

    Allergy measured using multi-choice question "do you have allergy?"

    Measured: Once at baseline

  83. Average physical activity

    Average number of hours of physical activity per week

    Measured: Once at baseline

  84. Average physical activity intensity

    Average physical activity intensity per week

    Measured: Once at baseline

  85. Average tabacco consumption

    Average number of cigarette per day

    Measured: Once at baseline

  86. Average alcohol consumption

    Average number of alcohol glasses per week

    Measured: Once at baseline

  87. Average cannabis consumption

    Average number of cannabis joint per week

    Measured: Once at baseline

  88. Average tea consumption

    Average number of cup of tea per day

    Measured: Once at baseline

  89. Average coffee consumption

    Average number of cup of coffee per day

    Measured: Once at baseline

  90. Average food consumption

    Average food consumption of 16 food groups

    Measured: Once at baseline

  91. Diet characterization

    "How do you characterize your diet" measured on a visual analogue scale ranging from 0 (Not at all balanced) to 100 (Very balanced)

    Measured: Once at baseline

  92. RPAQ questionnaire

    The Recent Physical Activity Questionnaire (RPAQ) assesses the level of physical activity and sedentary lifestyle in adults over the past four weeks. It is divided into three parts: work and study, home and leisure, and finally, stairs and travel. It makes it possible to classify individuals into several categories, one on sedentary lifestyle (low, resistant either 3-7h/day or high or >7h/day) and one on the level of physical activity (<8.3 Metabolic equivalent of task(MET).hour/week: inactive or >8.3 MET.h/wk: active).

    Measured: Once at baseline

  93. MBI questionnaire

    The Maslach Burn-out Inventory (MBI) is composed of 22 items designed to assess the three components of the burn-out syndrome: emotional exhaustion (9 items), depersonalization (5 items) and reduced personal accomplishment (8 items). The items are written in the form of statements about personal feelings or attitudes. Items are made of a 7-point scale frequency of feelings, varying from "never" to "every day". The scores for each component of the burn-out syndrome are considered separately. If desired for participant feedback, each score can be coded as low, average, or high.

    Measured: Once at baseline

  94. JDCS questionnaire

    The Job Demand-Control-Support (JDCS) questionnaire of Karasek assess job demands, job control and social support through 26 items. The questionnaire measures nine items of job demands, nine items of job control and eight items of social support. Items of JDCS are scored on a four-point Likert-type scale, ranging from 1 = strongly disagree to 4 = strongly agree. Among the 26 items, five negative statements require reverse scoring. From French data, the job strain threshold is set for a demands score higher than 20 and a control score lower than 71; the isostrain threshold is determined from a combining score of job strain and social support lower than 24. We would ask the participants to fulfil the questionnaire from memories that they keep of their work.

    Measured: Once at baseline

  95. ERI questionnaire

    The Effort-Reward Imbalance Questionnaire (ERI) is a self-administrated test assessing psychological distress and health problems that may occur when there is an imbalance between the efforts required by the work and the rewards received. We used the 46 items of the French version of the ERI model exploring efforts (six items), over commitment (eleven items), and rewards (seventeen items). Items of ERI were scored on a five-point Likert-type scale, ranging from 1 = disagree to 5 = agree and very disturbed. A ratio extrinsic efforts and rewards can assess the imbalance between these two dimensions. A ratio greater than one defines employees exposed to an imbalance between efforts and rewards.

    Measured: Once at baseline

  96. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 6 am, beginning of the control day

  97. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 6 am, beginning of the control day

  98. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 6 am, beginning of the control day

  99. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 6 am, beginning of the control day

  100. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 9 am on the control day

  101. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 9 am on the control day

  102. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 9 am on the control day

  103. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 9 am on the control day

  104. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 12 am on the control day

  105. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 12 am on the control day

  106. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 12 am on the control day

  107. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 12 am on the control day

  108. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 3 pm on the control day

  109. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 3 pm on the control day

  110. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 3 pm on the control day

  111. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 3 pm on the control day

  112. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 6 pm, end of the control day

  113. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 6 pm, end of the control day

  114. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 6 pm, end of the control day

  115. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 6 pm, end of the control day

  116. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 6 am, beginning of the sit-and-stand desk day

  117. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 6 am, beginning of the sit-and-stand desk day

  118. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 6 am, beginning of the sit-and-stand desk day

  119. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 6 am, beginning of the sit-and-stand desk day

  120. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 9 am on the sit-and-stand desk day

  121. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 9 am on the sit-and-stand desk day

  122. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 9 am on the sit-and-stand desk day

  123. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 9 am on the sit-and-stand desk day

  124. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 12 am on the sit-and-stand desk day

  125. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 12 am on the sit-and-stand desk day

  126. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 12 am on the sit-and-stand desk day

  127. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 12 am on the sit-and-stand desk day

  128. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 3 pm on the sit-and-stand desk day

  129. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 3 pm on the sit-and-stand desk day

  130. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 3 pm on the sit-and-stand desk day

  131. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 3 pm on the sit-and-stand desk day

  132. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 6 pm, end of the sit-and-stand desk day

  133. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 6 pm, end of the sit-and-stand desk day

  134. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 6 pm, end of the sit-and-stand desk day

  135. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 6 pm, end of the sit-and-stand desk day

  136. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 6 am, beginning of the cycloergometer day

  137. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 6 am, beginning of the cycloergometer day

  138. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 6 am, beginning of the cycloergometer day

  139. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 6 am, beginning of the cycloergometer day

  140. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 9 am on the cycloergometer day

  141. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 9 am on the cycloergometer day

  142. Salivary leptin

    Salivary leptin measured in ng/dml

    Measured: 9 am on the cycloergometer day

  143. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 9 am on the cycloergometer day

  144. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 12 am on the cycloergometer day

  145. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 12 am on the cycloergometer day

  146. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 12 am on the cycloergometer day

  147. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 12 am on the cycloergometer day

  148. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 3 pm on the cycloergometer day

  149. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 3 pm on the cycloergometer day

  150. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 3 pm on the cycloergometer day

  151. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 3 pm on the cycloergometer day

  152. Salivary cortisol

    Salivary cortisol measured in µg/dl

    Measured: 6 pm, end of the cycloergometer day

  153. Salivary DHEAS

    Salivary DHEAS measured in pg/ml

    Measured: 6 pm, end of the cycloergometer day

  154. Salivary leptin

    Salivary leptin measured in ng/ml

    Measured: 6 pm, end of the cycloergometer day

  155. Salivary ghrelin

    Salivary ghrelin measured in ng/ml

    Measured: 6 pm, end of the cycloergometer day

  156. Blood cortisol

    Blood cortisol measured in ng/ml or nmol/l

    Measured: 6 am, beginning of the cycloergometer day

  157. Blood cortisol

    Blood cortisol measured in ng/ml or nmol/l

    Measured: 6 pm, end of the cycloergometer day

  158. Blood DHEAS

    Blood DHEAS measured in µg/ml

    Measured: 6 am, beginning of the cycloergometer day

  159. Blood DHEAS

    Blood DHEAS measured in µg/ml

    Measured: 6 pm, end of the cycloergometer day

  160. Blood leptin

    Blood leptin measured in ng/ml

    Measured: 6 am, beginning of the cycloergometer day

  161. Blood leptin

    Blood leptin measured in ng/ml

    Measured: 6 pm, end of the cycloergometer day

  162. Blood ghrelin

    Blood ghrelin measured in pg/ml

    Measured: 6 am, beginning of the cycloergometer day

  163. Blood ghrelin

    Blood ghrelin measured in pg/ml

    Measured: 6 pm, end of the cycloergometer day

  164. Blood BDNF

    Blood brain-derived neurotrophic factor (BDNF) measured in pg/ml

    Measured: 6 am, beginning of the cycloergometer day

  165. Blood BDNF

    Blood brain-derived neurotrophic factor (BDNF) measured in pg/ml

    Measured: 6 pm, end of the cycloergometer day

  166. Blood pro-inflammatory cytokines

    Blood pro-inflammatory cytokines measured in pg/ml

    Measured: 6 am, beginning of the cycloergometer day

  167. Blood pro-inflammatory cytokines

    Blood pro-inflammatory cytokines measured in pg/ml

    Measured: 6 pm, end of the cycloergometer day

  168. Blood NPY

    Blood vascular distribution of neuropeptide Y (NPY) measured in pg/ml

    Measured: 6 am, beginning of the cycloergometer day

  169. Blood NPY

    Blood vascular distribution of neuropeptide Y (NPY) measured in pg/ml

    Measured: 6 pm, end of the cycloergometer day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jul 2023
  2. Study start7 Mar 2024
  3. Primary completionMar 2027 (estimated)
  4. Study completionJun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
36 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05931406
Sponsor's protocol ID
RBHP 2022 DUTHEIL
Other IDs
2022-A02730-43
Acronym
SECODIS
Status last verified
Sep 2026
First submitted
9 Jun 2023
Last updated
10 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: After contacting the corresponding author and signing a data sharing agreement, investigators will make available the documents and personal data strictly necessary in accordance with laws and regulations (Articles L.1121-3 and R.5121-13 of the Code of Public Health).

Publications

  • Clinchamps M, Bouillon-Minois JB, Trousselard M, Schmidt J, Pic D, Taillandier T, Mermillod M, Pereira B, Dutheil F. Effects of a sedentary behaviour intervention in emergency dispatch centre phone operators: a study protocol for the SECODIS randomised controlled cross-over trial. BMJ Open. 2024 Oct 9;14(10):e080177. doi: 10.1136/bmjopen-2023-080177.

    PubMed 39384224

Questions about this trial

What is this clinical trial studying?

A study testing Sit-and-stand desk and Cycloergometer in people with Sedentary Behavior and Occupational Stress, run by University Hospital, Clermont-Ferrand at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Lise LACLAUTRE (334.73.754.963, promo_interne_drci@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sedentary behavior (time frame: 12 hours of work corresponding to the control condition). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05931406, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in